Floatz logo

MIDAZOLAM

Sleep Disturbance

Sixth Affiliated Hospital, Sun Yat-sen UniversitySmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Sleep Disturbance cohort.

Asset / SponsorPhaseRating
Trazodone
Johns Hopkins University
Phase 4BB
Armodafinil
Cephalon
Phase 4BB
Tvp-1012
Technische Universität Dresden
Phase 4BB
MELATONIN
Duke University
Phase 3BB
Olanzapine
Central Institute of Psychiatry, Ranchi, India
Phase 4BB

View all 36 →

Same molecule, other indications

MIDAZOLAM is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
75 / 100
View asset →
neuralgiaDormant
BBB
Indicative ·
75 / 100
View asset →
epilepsyDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →